Incruse Ellipta umeclidinium bromide regulatory update

Japan approved Encruse Ellipta umeclidinium bromide from GlaxoSmithKline to treat symptoms due to airway obstruction with chronic obstructive pulmonary disorder (COPD). The company said it plans to la...